Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

t tell B-cells to grow and divide, uncontrollably. This therapy can help stop cancer progression while preserving normal, healthy cells. Ibrutinib is a first in its class, oral therapy and is a new agent that inhibits the B-cell receptor signaling complex that plays an important role in the survival of malignant B-cells.  It is one of the first medicines to file for FDA approval via the new Breakthrough Therapy Designation pathway, bringing new hope to many suffering from CLL and other B-cell malignancies.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

We strive to be allies to all of our stakeholders – most importantly patients waging struggles against rare and incurable cancers – but also the physicians and family members who care for them, payers, our employees, our shareholders, and regulatory agencies working to bring life-changing medicines to patients.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDA
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
(Date:12/22/2014)... SAN DIEGO , Dec. 22, 2014  Pfenex ... Px563L, Pfenex,s recombinant anthrax vaccine, has been filed and ... additional funding provided by the Department of Health and ... Development Authority (BARDA). "We are extremely pleased ... anthrax vaccine, Px563L.  This represents a significant milestone in ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... Ill. (PRWEB) December 21, 2014 ... recommendations for chest computed tomography (CT) to evaluate ... relevant findings, including cancer, according to a new ... , Researchers said the findings show that radiologist ... represent valuable contributions to patient care. , RAIs, ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 In ... is segmented by power source, product, and application. ... electric-powered, battery-powered, and pneumatic instruments. By product, the ... and accessories segments. The handpieces market is further ... devices, suction coagulators, laparoscopic instruments, shavers, wire/pin drivers, ...
(Date:12/21/2014)... Beverly Hills, Ca (PRWEB) December 21, 2014 ... Dr. Khanna was a guest at the Aspen Helicopters ... for kids and a Santa with sleigh, flown by ... the helicopter appeared invisible; only Santa with sleigh was ... both during day and night. Dr.Khanna has helped many ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Faced with a barrage of pressing issues, the ... agenda. The timing bodes well for change, according ... University Center for Health Policy and Professionalism, associate professor ... a pediatrician at Riley Hospital for Children. , "If ...
... Feb. 6 Turner Construction Company, the nation,s leading ... Northern Inyo Hospital to proceed with the $42 million ... for Phase Two will start in March 2009 with ... of a new central plant, emergency rooms, ICU, CCU, ...
... Colo., Feb. 6 Baxa Corporation, an Englewood Colorado-based medical ... of the Top 50 Family-Owned Companies in Colorado. Qualifying ... be controlled by a single family, and controlling family members ... has to have been involved in the company for at ...
... Medical Group Inc.,(OTC Bulletin Board: WMDG; "Winner Medical"), ... and wound care products) in China, today,announced that ... first quarter,ended December 31, 2008 on Friday, February ... The earnings release will be available on the ...
... (Nasdaq: EVVV ) will release its 2008 fourth ... 2009 on Tuesday, Febuary 24, 2009, before regular market trading ... same day at 7:30 a.m. Central Time (8:30 a.m. Eastern ... full-year operating results and future outlook, followed by a question ...
... ... Brookfield, Wisconsin (PRWEB) February 6, 2009 -- Watching your weight? ... International Foundation of Employee Benefits Plans found that of those ... loss program., , ,When asked their primary reason for offering a ...
Cached Medicine News:Health News:Prioritizing health-care reform components 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 3Health News:Winner Medical Schedules 2008/2009 First Quarter Earnings Release on Friday, February 13, 2009 2Health News:ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: